Loading
The trial of 644 women with newly metastatic triple-negative breast cancer who could not have immunotherapy, in which the antibody-drug conjugate datopotamab deruxtecan held the cancer still for 10.8 months against 5.6 with chemotherapy and lengthened life from 18.7 to 23.7 months.
TROPION-Breast02 (Dent, Shao, Schmid, Cortes and colleagues) randomised 644 patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer for whom immunotherapy was not an option, between 16 May 2022 and 11 June 2024, to datopotamab deruxtecan 6 mg/kg every three weeks (323) or investigator's choice of chemotherapy (321), stratified by geography, disease-free interval and PD-L1 status; dual primary endpoints were progression-free survival by blinded independent central review and overall survival. Median progression-free survival was 10.8 months (95 percent confidence interval 8.6 to 13.0) versus 5.6 months (5.0 to 7.0), hazard ratio 0.57 (99 percent CI 0.44 to 0.73, p<0.0001); median overall survival 23.7 months (19.8 to 25.6) versus 18.7 months (16.0 to 21.8), hazard ratio 0.79 (95.01 percent CI 0.64 to 0.98, p=0.029). Grade 3 or higher treatment-related adverse events occurred in 33 versus 29 percent, led to discontinuation in 4 versus 7 percent, and there were no treatment-related deaths.
The first-line overall survival result that made an antibody-drug conjugate the standard for PD-L1-negative or immunotherapy-ineligible metastatic triple-negative disease, and the reason the sequencing question (which TROP2 drug first, what after it) is now urgent.
Shares Peter Schmid, Javier Cortés, Annals of Oncology, Progression-free survival (PFS) and the tag tnbc-evidence.
Shares ASCENT-03, TROPION-Breast02, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Trials that include, and report, brain metastases in triple-negative breast cancer, Overall survival (OS), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Rebecca Dent, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Annals of Oncology, Overall survival (OS), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, AstraZeneca and the tag tnbc-evidence.
Shares Annals of Oncology, Overall survival (OS), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, AstraZeneca and the tag tnbc-evidence.
Shares Daiichi Sankyo, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, AstraZeneca, Antibody-drug conjugate (ADC) and the tag tnbc-evidence.
Shares Javier Cortés, Annals of Oncology, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.